🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🔊🔊 New manuscript alert! For a side project during my PhD we explored novel 7-deaza ribonucleosides with dual N6/C7 substitutions and serendipiously discovered nucleosides with a cool tricyclic base. Check it out now in ACS Med Chem Letters: pubs.acs.org/doi/10.1021/ac…

Meet with Astrocyte Pharmaceuticals at #ASCPT2024! Astrocyte’s Lisa Manna will be presenting our poster with QPS on the Phase 1B trial of AST-004, and its innovative use of serial CSF collection!

Cryo-EM A3 adenosine receptor structures, from SIMM, with both of the potent and selective A3 agonists that are in advanced clinical trials by CanFite. We invented both molecules, and they are widely used in research, as well: IB-MECA and Cl-IB-MECA. doi.org/10.1038/s41467…

NIDDK scientists introduce “lipid trolling” to improve potency & efficacy of PAMs (positive allosteric modulators) of the A3 adenosine receptor, which have potential to treat inflammation, liver disease, ischemia & chronic pain ACS Publications Bio & Med Chem Content #JMedChem pubs.acs.org/doi/epdf/10.10…]

For the 1st time, OHSU News & NIDDK researchers uncovered the human dopamine transporter (hDAT)’s 3D structure, which controls dopamine uptake (a transmitter affecting mood), unveiling how it binds to small molecules & ions in a collaborative nature study nature.com/articles/s4158…

NIDDK research out now in Nature Chemical Biology: Selective Bioorthogonal Probe for N-Glycan Hybrid Structures. nature.com/articles/s4158…

In Journal of Medicinal Chemistry: NIDDK researchers discovered a new class of molecules, derived from existing antiviral and cancer drugs, that may lead to future therapeutics for fibrosis-related cardiopulmonary, vascular, & renal conditions. pubs.acs.org/doi/10.1021/ac… JMedChem

Serotonin, a molecule known for its regulation of neural activity and mood, can also cause inflammation. With reengineered molecules, the researchers blocked an inflammatory serotonin pathway at specific receptors outside the brain.

The researchers believe that studying these new molecules could lead to future treatment strategies for pulmonary arterial hypertension and other fibrosis-related conditions. Additional studies are planned to further optimize the drugs by chemical modification.

Researchers from Saint Louis University and NIDDK discovered activating a mitochondrial adenosine receptor (A3AR) protects rodent neurons from chemotherapy-induced neurotoxicity (CIPN), a common cause of nerve pain in cancer patients jneurosci.org/content/early/… SfN Journals

In an NIDDK study conducted with international support, researchers invented a light-activated psoriasis drug to selectively target skin lesions in a mouse model of psoriasis, reducing the likelihood of undesirable side effects. pubs.acs.org/doi/10.1021/ja… ACS Publications

Beautiful excursion into the history and importance of Photoremovable Protecting Groups: pubs.acs.org/doi/10.1021/ja… One of the best papers I have read this year. Congratulations to authors!

irp.nih.gov/blog/post/2025… Photoswitchable A3 adenosine receptor agonist NIH Intramural

Summary of Astrocyte's Phase 1A clinical trial of AST-004 featured this month in Stroke AHA/ASA's Article Commentary. For the Phase 1B study that also showed high safety and tolerability of extending dosing, the manuscript is in preparation - stay tuned! ahajournals.org/do/10.1161/blo…

A great week at the #TBIconference—Astrocyte was thrilled to be part of the scientific exchange and momentum driving new treatments forward. Dr. Korinek presented updates on the cerebroprotectant AST-004 advancing to Phase 2 clinical trials. #concussion #TBI #BrainHealth

Astrocytes have long been conceived as passive support player cells in the brain. But today Science Magazine (via 3 reports) they got a big upgrade for their active role in neuromodulation and control of brain function science.org/doi/10.1126/sc…

Astrocytes are stepping into the spotlight. 🌟 A trio of new Science papers reveals just how central these cells are to brain function—and why they may be the key to recovery after injury. Huge implications for TBI and stroke. science.org/doi/10.1126/sc…

Carolyn Bertozzi delivered an amazing Margaret Pittman lecture today at NIH, & succeeded to explain complicated bioorthogonal chemistry to the broader scientific audience.

🚀 More great news! Astrocyte Pharmaceuticals is honored to receive a $3M grant from the NIH to further advance the oral formulation of AST-004 toward an IND and the clinic! #concussion #TBI astrocytepharma.com/2025/06/astroc…

Great story by 7NEWS Adelaide covering Astrocyte Pharmaceuticals STARFAST Phase 2 clinical trial!! facebook.com/share/v/16Y4or…